CONMED Corporation (Nasdaq: CNMD), a medical technology
manufacturer and distributor of surgical devices and equipment,
announced today that Joseph J. Corasanti, President and Chief Executive
Officer of CONMED Corporation, will ring the ceremonial
Nasdaq opening
bell on Tuesday, July 24th at 9:30am ET at the NASDAQ Marketsite in
Times Square, New York City.
"CONMED is pleased to celebrate our 20th
anniversary on The NASDAQ Stock Market,” said
Mr. Corasanti. "When we were incorporated in 1970, we were solely
dedicated to the manufacturing of ECG monitoring electrodes. Today, with
3,200 employees, six manufacturing facilities, and sales locations
around the world, CONMED manufactures and distributes over 10,000
products in more than 100 countries. CONMED’s
products, many of which hold top market positions, are used by surgeons
and physicians in various specialties to facilitate surgical repairs,
diagnose medical problems and monitor patients’
vital signs. These innovative products have helped CONMED increase
revenues more than fifty fold to $647 million in 2006 annual sales from
$12 million in 1987.”
Continued innovation and commercialization of new proprietary products
and processes are essential elements of CONMED’s
success to date and long-term growth strategy. The Company has pioneered
numerous medical devices that improve patient outcomes while providing
cost efficient solutions for healthcare providers. Most recently, CONMED
launched the IM4000 High Definition minimally invasive Camera System,
its first high definition camera system used in multi-specialty
endoscopy and arthroscopy.
Mr. Corasanti added, ”Since our first public
offering 20 years ago, CONMED’s initial public
market shareholders have realized an approximate 1,200% overall return
as compared to 500% for the overall NASDAQ market and 400% for the S&P
500 for the same period. CONMED’s ability to
access the capital markets through NASDAQ has been a critical component
to our business strategy and growth over the past 20 years. We look
forward to extending our continued relationship with NASDAQ into the
future.” CONMED Profile
CONMED is a medical technology company with an emphasis on surgical
devices and equipment for minimally invasive procedures and monitoring.
The Company’s products serve the clinical
areas of arthroscopy, powered surgical instruments, electrosurgery,
cardiac monitoring disposables, endosurgery and endoscopic technologies.
They are used by surgeons and physicians in a variety of specialties
including orthopedics, general surgery, gynecology, neurosurgery, and
gastroenterology. Headquartered in Utica, New York, the Company’s
3,200 employees distribute its products worldwide from several
manufacturing locations.
Forward Looking Information This press release contains forward-looking statements based on
certain assumptions and contingencies that involve risks and
uncertainties. The forward-looking statements are made pursuant
to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995 and relate to the Company’s
performance on a going-forward basis. The forward-looking
statements in this press release involve risks and uncertainties which
could cause actual results, performance or trends, to differ materially
from those expressed in the forward-looking statements herein or in
previous disclosures. The Company believes that all
forward-looking statements made by it have a reasonable basis, but there
can be no assurance that management’s
expectations, beliefs or projections as expressed in the forward-looking
statements will actually occur or prove to be correct. In
addition to general industry and economic conditions, factors that could
cause actual results to differ materially from those discussed in the
forward-looking statements in this press release include, but are not
limited to: (i) the failure of any one or more of the assumptions stated
above, to prove to be correct; (ii) the risks relating to
forward-looking statements discussed in the Company’s
Annual Report on Form 10-K for the fiscal year ended December 31, 2006;
(iii) cyclical purchasing patterns from customers, end-users and dealers; (iv) timely release of new products, and acceptance of such new
products by the market; (v) the introduction of new products by
competitors and other competitive responses; (vi) the possibility that
any new acquisition or other transaction may require the Company to
reconsider its financial assumptions and goals/targets; and/or (vii) the
Company’s ability to devise and execute
strategies to respond to market conditions.
